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Abstract
Interferon-k4-related dinucleotide variant rs368234815 TT/-G is
strongly linked with rs12979860 polymorphism, the most impor-
tant genetic marker connected to treatment-induced hepatitis
C virus clearance. Due to additional baseline information that
rs368234815 polymorphism could provide for the management
of chronic hepatitis C, we developed and validated a high-
resolution melting genotyping assay using 193 patients with
chronic hepatitis C.
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Genome-wide association studies showed that the single
nucleotide polymorphism rs12979860 near to interleukin-28B
gene (IL28B) was the most important genetic marker of
spontaneous and interferon-induced clearance of hepatitis C
virus (HCV) [1–4]. However, whether rs12979860 exerts
biological effects or whether it is in linkage disequilibrium with
other functional polymorphisms was unknown. Recently, two
publications have described the identiﬁcation of a novel
dinucleotide variant rs368234815 TT/-G (previously desig-
nated as ss469415590) that is in strong linkage disequilibrium
with the rs12979860 polymorphism and probably has a
functional mechanism. In the ﬁrst study Prokunina-Olsson
et al. [5] showed that the rs368234815[-G] allele, which marks
the unfavourable rs12979860[T], by frameshift mutation
creates the new interferon-k4 (IFNL4) gene encoding the
IFN-k4 protein, which could be a direct indicator of HCV
IFN-based treatment failure by weak induction of the
IFN-stimulated genes. In the second study [6] the
rs368234815 TT/-G polymorphism was also found to promote
the methylation of a cytosine residue and affect both IL28B and
IFN-c-inducible protein 10 mRNA expression in peripheral
blood mononuclear cells stimulated with the dsRNA analogue
poly(I:C). Both studies shared the conclusion that
rs368234815 TT/-G polymorphism is a better marker for
HCV clearance than rs12979860. More recent publications [7–
10] conﬁrm the association of IFNL4 rs368234815 with both
IFN-induced and spontaneous clearance of HCV infection, so
we developed a real-time genotyping assay with detection
based on post-PCR high-resolution melting (HRM) analysis by
using a well-characterized cohort of 193 chronic hepatitis C
patients treated with pegylated IFN-a and ribavirin (pegIFN-a/
RBV) for 48 weeks [11,12].
High-resolution melting analysis is a fast and powerful
technique able to distinguish wild-type and mutant variants in
the presence of DNA binding dye that does not interact with
ssDNA, but ﬂuoresces strongly in the presence of dsDNA.
Notably, the HRM method in terms of cost per sample is
lower than other genotyping technologies, such as sequencing
and hydrolysis single nucleotide polymorphism analysis (Taq-
Man).
To design the HRM assay, we considered that the amplicon
around the mutation site should be possibly not longer than
100 bp and that the 1 bp difference must result in visible
melting temperature differences, as far as possible >0.1°C. Yet,
we also took into account the presence of two variants near to
rs368234815 target site (rs73555604 and rs4803221) [5] that
could affect the results of HRM genotyping assay in unex-
pected ways. Hence, we designed the primers both to limit the
amplicon length to a short 63-bp region and to include the two
variants surrounding the rs368234815 polymorphism site as
degenerate positions (Table 1).
The HRM assay was evaluated using nucleic acid samples
extracted from peripheral blood mononuclear cells of the 193
patients by the phenol–chloroform method. Patients gave
written informed consent for participation in this study, which
was approved by the local Institutional Review Board of the
Department of Internal Medicine, operated according to the
principles outlined in the Declaration of Helsinki. All extracted
DNA samples were analysed for purity and yield via absor-
bance spectroscopy (A260/A280) using the NanoDrop ND
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1000 spectrophotometer (Thermo Fisher Scientiﬁc, Waltham,
MA). Real-time PCR and HRM were carried out using a
Light-Cycler Nano System (Roche, Mannheim, Germany) on
20 lL of reaction mixture containing 19 LightCycler
high-resolution Master kit with LightCycler 480 Resolight
Dye (Roche, Mannheim, Germany), 0.2 lM each primer
(rs368234815HRM-F and rs368234815HRM-R), 2.5 mM
MgCl2 and 1 lL of 10 ng/lL of the extracted DNA as input.
Importantly, to achieve the best results, the amount of input
DNA should be adjusted to be similar for all samples within
any one run. The thermal cycling conditions include an initial
hold at 95°C for 10 min, followed by 45 cycles of 95°C for
10 s (denaturation), 60°C for 15 s (annealing), and extension
step of 72°C for 20 s. Acquisition of the ﬂuorescence signal
was performed during each extension step. Ampliﬁcation was
followed by HRM analysis of the real-time PCR products,
consisting of a denaturation step at 95°C for 60 s, a cooling
step at 40°C for 60 s, a short hold at 60°C for 1 s and a
continuous acquisition step from 60°C to 95°C at a ramp rate
of 0.3°C/s. By using speciﬁc setting ranges for pre-melt and
post-melt temperatures of 81.1–84.1°C and 92.5–94.4°C,
respectively, it was possible to distinguish clearly the
rs368234815 TT/TT, TT/-G and -G/-G genotypes in the
normalized difference plot (Fig. 1).
The genotyping success rate of rs368234815 by HRM assay
was 100% and no deviation from Hardy–Weinberg equilibrium
(p >0.05) was observed. Sanger sequencing control performed
with Seq-primers (Table 1) on 100 randomly picked samples,
obtained a 100% concordance with genotypes from HRM. The
genotypic frequencies of rs368234815 variant (37% for TT/TT,
49.5% for TT/-G and 13.5% for -G/-G) matched that of
rs12979860 polymorphism (37% for CC, 50% for CT and 13%
for TT) achieved previously by TaqMan assay [12], conﬁrming
their high linkage disequilibrium (Table 2). As the only patient
with mismatched genotype was a non-responder to combined
treatment, the predictive value of the IFNL4 rs368234815 and
rs12979860 variants is not different in our cohort.
Treatment of chronic hepatitis C infection is rapidly
evolving towards IFN-free, direct-acting antiviral (DAA)
regimens that speciﬁcally target the HCV protease (NS3/4A)
(e.g. Telaprevir and Boceprevir), RNA polymerase (NS5B) (e.g.
Sofosbuvir), or non-structural protein NS5A (e.g. Daclatasvir).
Although phase 2 and 3 studies of all oral IFN-free regimens
have repeatedly shown optimal efﬁcacy and tolerability rates
[13], access to these therapies is unlikely to be universal in
many countries because of cost issues. The ability to predict
treatment efﬁcacy and rate of HCV RNA decline during
Telaprevir- and Sofosbuvir-based therapies using the IFNL4
genotype could therefore be clinically useful [14,15], as
prediction of efﬁcacy of IFN-based regimens might still have
FIG. 1. Representative difference graph for DNA samples from
hepatitis C virus (HCV) infected patients carrying different
rs368234815 genotypes (TT/TT: red lines, TT/-G: blue lines and -G/
-G: green lines), was achieved using the LightCycler NanoSW1.1
software (Roche, Mannheim, Germany) by subtracting the normalized
ﬂuorescence data of the TT/TT genotype, selected as a baseline, from
that of each of the other samples in the high-resolution melting
analysis. The position of each sample relative to the baseline is plotted
against the temperature to generate a difference plot that helps to
cluster samples manually into groups that have similar melting curves
(e.g., those with the same genotype).
TABLE 2. Genotype distribution and linkage disequilibrium
of rs368234815 and rs12979860 variants
TaqMan assay for rs12979860
TotalCC CT TT
HRM assay for rs368234815
TT/TT 72 0 0 72
TT/G 0 95 0 95
G/G 0 1 25 26
Total 72 96 25 LDa (r2 = 0.98)
aThe r2 coefﬁcient of LD was calculated as described elsewhere [17].
TABLE 1. Primer sequences for high-resolution melting
assay, presequencing PCR and cycle sequencing
Primer Nucleotide sequence (50–30)
Amplicon
length (bp)
rs368234815HRM-F CTGTGGGTCCTGTRCACGGT 63
rs368234815HRM-R CGGTAGTGSGAGAGCAGGCA
rs368234815Seq-Fa TCACGCTCCGAGCATTGCCT 903
rs368234815Seq-R GGCCGCTGAGCACTGCCT
Degenerate nucleotides for rs73555604 and rs4803221 variants are in bold:
R = G or A; S = C or G.
aCycle sequencing primer.
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a place for treatment allocation. Nevertheless, at the current
time, the rs368234815 variant is not considered a key
diagnostic test in the treatment decision algorithm [16].
In summary, we developed a sensitive, cost-effective HRM
genotyping assay for the novel IFNL4 rs368234815 polymor-
phism that can be adopted only in virological laboratories with
HRM capability to provide additional baseline information for
the management of patients with chronic hepatitis C.
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